OSE Immunotherapeutics (OSE.PA) Tuesday said that Marc Le Bozec has been appointed as its permanent Chief Executive Officer, or CEO, with immediate effect, transitioning from his role as the interim CEO.
The company said that Le Bozec had been serving as interim CEO since October 2, 2025. Following a comprehensive review of both internal and external candidates, and based on the recommendation of the Nomination and Compensation Committee, the company's Board of Directors unanimously approved his appointment as permanent CEO.
On the Paris Exchange, OSE.PA is currently trading at 4.0660 euros, up 3.9 percent.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.